1189 related articles for article (PubMed ID: 19636022)
21. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
22. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.
Drevs J; Siegert P; Medinger M; Mross K; Strecker R; Zirrgiebel U; Harder J; Blum H; Robertson J; Jürgensmeier JM; Puchalski TA; Young H; Saunders O; Unger C
J Clin Oncol; 2007 Jul; 25(21):3045-54. PubMed ID: 17634482
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors.
Steeghs N; Gelderblom H; Wessels J; Eskens FA; de Bont N; Nortier JW; Guchelaar HJ
Invest New Drugs; 2011 Feb; 29(1):137-43. PubMed ID: 19924384
[TBL] [Abstract][Full Text] [Related]
24. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
Carducci MA; Musib L; Kies MS; Pili R; Truong M; Brahmer JR; Cole P; Sullivan R; Riddle J; Schmidt J; Enas N; Sinha V; Thornton DE; Herbst RS
J Clin Oncol; 2006 Sep; 24(25):4092-9. PubMed ID: 16943527
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy.
Levine AM; Tulpule A; Quinn DI; Gorospe G; Smith DL; Hornor L; Boswell WD; Espina BM; Groshen SG; Masood R; Gill PS
J Clin Oncol; 2006 Apr; 24(11):1712-9. PubMed ID: 16520466
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
Peterson AC; Swiger S; Stadler WM; Medved M; Karczmar G; Gajewski TF
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4048-54. PubMed ID: 15217937
[TBL] [Abstract][Full Text] [Related]
27. Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416.
Dowlati A; Robertson K; Radivoyevitch T; Waas J; Ziats NP; Hartman P; Abdul-Karim FW; Wasman JK; Jesberger J; Lewin J; McCrae K; Ivy P; Remick SC
Clin Cancer Res; 2005 Nov; 11(21):7938-44. PubMed ID: 16278419
[TBL] [Abstract][Full Text] [Related]
28. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors.
Rosen LS; Senzer N; Mekhail T; Ganapathi R; Chai F; Savage RE; Waghorne C; Abbadessa G; Schwartz B; Dreicer R
Clin Cancer Res; 2011 Dec; 17(24):7754-64. PubMed ID: 21976535
[TBL] [Abstract][Full Text] [Related]
29. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma.
Posey JA; Ng TC; Yang B; Khazaeli MB; Carpenter MD; Fox F; Needle M; Waksal H; LoBuglio AF
Clin Cancer Res; 2003 Apr; 9(4):1323-32. PubMed ID: 12684400
[TBL] [Abstract][Full Text] [Related]
30. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
Burris HA; Hurwitz HI; Dees EC; Dowlati A; Blackwell KL; O'Neil B; Marcom PK; Ellis MJ; Overmoyer B; Jones SF; Harris JL; Smith DA; Koch KM; Stead A; Mangum S; Spector NL
J Clin Oncol; 2005 Aug; 23(23):5305-13. PubMed ID: 15955900
[TBL] [Abstract][Full Text] [Related]
31. Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.
Langenberg MHG; Witteveen PO; Roodhart J; Lolkema MP; Verheul HMW; Mergui-Roelvink M; Brendel E; Krätzschmar J; Loembé B; Nol-Boekel A; Christensen O; Schellens JHM; Voest EE
Ann Oncol; 2011 Nov; 22(11):2508-2515. PubMed ID: 21378200
[TBL] [Abstract][Full Text] [Related]
32. Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours.
Strumberg D; Schultheis B; Adamietz IA; Christensen O; Buechert M; Kraetzschmar J; Rajagopalan P; Ludwig M; Frost A; Steinbild S; Scheulen ME; Mross K
Br J Cancer; 2008 Nov; 99(10):1579-85. PubMed ID: 19002179
[TBL] [Abstract][Full Text] [Related]
33. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.
Liu G; Rugo HS; Wilding G; McShane TM; Evelhoch JL; Ng C; Jackson E; Kelcz F; Yeh BM; Lee FT; Charnsangavej C; Park JW; Ashton EA; Steinfeldt HM; Pithavala YK; Reich SD; Herbst RS
J Clin Oncol; 2005 Aug; 23(24):5464-73. PubMed ID: 16027440
[TBL] [Abstract][Full Text] [Related]
34. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.
Awada A; Hendlisz A; Gil T; Bartholomeus S; Mano M; de Valeriola D; Strumberg D; Brendel E; Haase CG; Schwartz B; Piccart M
Br J Cancer; 2005 May; 92(10):1855-61. PubMed ID: 15870716
[TBL] [Abstract][Full Text] [Related]
35. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
[TBL] [Abstract][Full Text] [Related]
36. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
[TBL] [Abstract][Full Text] [Related]
37. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
[TBL] [Abstract][Full Text] [Related]
38. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
Stopeck A; Sheldon M; Vahedian M; Cropp G; Gosalia R; Hannah A
Clin Cancer Res; 2002 Sep; 8(9):2798-805. PubMed ID: 12231519
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Giles FJ; Cooper MA; Silverman L; Karp JE; Lancet JE; Zangari M; Shami PJ; Khan KD; Hannah AL; Cherrington JM; Thomas DA; Garcia-Manero G; Albitar M; Kantarjian HM; Stopeck AT
Cancer; 2003 Apr; 97(8):1920-8. PubMed ID: 12673719
[TBL] [Abstract][Full Text] [Related]
40. Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
Hoekstra R; Dumez H; Eskens FA; van der Gaast A; Planting AS; de Heus G; Sizer KC; Ravera C; Vaidyanathan S; Bucana C; Fidler IJ; van Oosterom AT; Verweij J
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6908-15. PubMed ID: 16203782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]